Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online before print March 14, 2002, 10.1148/radiol.2232010801
This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2232010801v1
223/2/532    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blachar, A.
Right arrow Articles by Li, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blachar, A.
Right arrow Articles by Li, W.
(Radiology 2002;223:532-539.)
© RSNA, 2002


Gastrointestinal Imaging

Radiologists’ Performance in the Diagnosis of Liver Tumors with Central Scars by Using Specific CT Criteria1

Arye Blachar, MD, Michael P. Federle, MD, James V. Ferris, MD, Joan M. Lacomis, MD, John S. Waltz, MD, Derek R. Armfield, MD, Gorden Chu, MD, Omar Almusa, MD, Luigi Grazioli, MD, Eric Balzano, MD and Wei Li, PhD

1 From the Departments of Radiology (A.B., M.P.F., J.V.F., J.M.L., J.S.W., D.R.A., G.C., O.A., E.B.) and Biostatistics (W.L.), University of Pittsburgh Medical Center, 200 Lothrop St, Pittsburgh, PA 15213; and Department of Radiology, Spedali Civili Brescia, Italy (L.G.). Received April 17, 2001; revision requested June 5; revision received September 17; accepted October 10. Address correspondence to M.P.F. (e-mail: federle@pitt.edu).


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
PURPOSE: To determine the performance of radiologists with differing levels of expertise in the diagnosis of the most common types of liver tumors with central scars (ie, focal nodular hyperplasia [FNH], fibrolamellar hepatocellular carcinoma [HCC], and large hepatic hemangioma) by using specific computed tomographic (CT) findings.

MATERIALS AND METHODS: Review of medical records at the University of Pittsburgh Medical Center identified patients with a total of 64 liver tumors that had central scars—including 29 cases of FNH, 20 fibrolamellar HCCs, and 15 large (>3.5 cm in diameter) hemangiomas—and with CT scans available for review. Retrospective review of these scans was performed individually by six radiologists who were blinded to the diagnosis, including two faculty abdominal radiologists, one abdominal imaging fellow, and three radiology residents. Individual performance was evaluated by means of receiver operating characteristic analysis, and interobserver agreement was measured by using the Cronbach {alpha}. Individual CT findings that may allow differentiation of tumor types were identified with the Kruskal-Wallis test.

RESULTS: CT allowed good to excellent interobserver agreement in the diagnosis of tumor type and in recognition of differential findings among the three types. The individual accuracy of diagnosis was very good, with the average area under the receiver operating characteristic curve ranging from 0.81 to 0.90. Although the faculty radiologists performed the best, the differences in performance between the subgroups of readers and the levels of confidence in diagnosis were not statistically significant. The diagnosis of fibrolamellar HCC was the most accurate and had the highest sensitivity, followed by FNH and large hemangioma. Clinical and CT findings that were found to be statistically significant in differentiating tumor types were patient age and sex, tumor size larger than 10 cm, width of tumor scars, invasion of vessels, nodular centripetal enhancement, marked hyperattenuation on arterial phase images, lymphadenopathy, heterogeneity, extrahepatic metastases, surface lobulation, calcification, and isoattenuation with liver tissue on portal venous phase images.

CONCLUSION: CT allows accurate differentiation of the most common types of liver tumors with central scars, including FNH, fibrolamellar HCC, and large hemangioma.

© RSNA, 2002

Index terms: Diagnostic radiology, observer performance • Liver, focal nodular hyperplasia, 761.3198 • Liver, hemangioma, 761.3194 • Liver neoplasms, CT, 761.12111, 761.12114 • Liver neoplasms, diagnosis, 761.3194, 761.3198, 761.323


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
A central area of scarring has been described in several types of liver tumors, including (most frequently) focal nodular hyperplasia (FNH) (18), fibrolamellar hepatocellular carcinoma (HCC) (913), and large hemangioma (1419). Rarely, a central scar may be seen in cholangiocarcinoma (8,20), some hepatic metastases (8,20), and conventional nonfibrolamellar HCC (15). Focal scars may develop in tumors with an abundance of fibrous stroma, in large tumors that outgrow their blood supply during the process of tissue repair, and in FNH after obliteration of central tumor vessels (21).

Regardless of their cause, scars within hepatic tumors are usually hypoattenuating compared with both the surrounding tumor and the normal liver parenchyma on unenhanced and contrast material–enhanced computed tomographic (CT) images. A characteristic feature of fibrous scar tissue within hepatic tumors is delayed and prolonged enhancement with intravenous contrast material (2022). This feature differentiates central scarring from central necrosis, which is also seen in large tumors but does not demonstrate delayed contrast material retention.

Distinguishing FNH, fibrolamellar HCC, and hemangioma is important because benign lesions usually require no treatment, while fibrolamellar HCC requires aggressive surgical resection. Because all three types of tumors occur in noncirrhotic livers, have no associated serum markers, and are often classified as hypervascular, accurate diagnosis with the use of noninvasive tests has been considered difficult (5).

The purpose of our study was to determine the performance of radiologists with varying levels of expertise in the diagnosis of the most common types of liver tumors with central scars (ie, FNH, fibrolamellar HCC, and large hemangioma) by using specific CT findings that have been reported as typical of these tumors (119). Our hypothesis was that use of these CT criteria would allow accurate diagnosis of the type of tumor, thereby enabling appropriate management.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Study Population
We (A.B., E.B., M.P.F.) reviewed the electronic medical records (ie, radiologic, surgical, and pathologic reports and discharge summaries) from January 1985 to March 2000 at the University of Pittsburgh Medical Center to identify all patients with a diagnosis of FNH, fibrolamellar HCC, or cavernous hemangioma (>3.5 cm in diameter) by using the name of the tumor and "central scar" as the search terms. Investigators not involved in the blinded interpretation (A.B., M.P.F., L.G.) then reviewed any available CT scans for these patients and, by consensus, selected for subsequent interpretation and scoring all cases that were determined to demonstrate a tumor with a scar. A central scar was defined as a central or eccentric focus within the tumor that was hypoattenuating compared with the tumor tissue and hepatic parenchyma on unenhanced and enhanced CT scans.

The study was approved by our institutional review board, and informed patient consent was not required or obtained.

Review resulted in 90 patients with a diagnosis of FNH. Sixty-five of these patients had undergone abdominal CT. Of these 65 patients, 13 were excluded because of lack of presurgical imaging (n = 7) or because the images could not be located (n = 6). Ten patients without pathologic proof of FNH were excluded because they had insufficient imaging follow-up. Twenty-nine of the remaining 42 patients had FNH with a scar (Fig 1), and these patients were included in our study. Nine patients with FNH underwent resection, 12 patients underwent core biopsy, and eight patients had no pathologic proof of FNH, but their conditions were stable during a follow-up of 1–6 years (mean follow-up, 2.5 years). All of the excised areas of FNH had a distinct central scar and radiating fibrous septa.



View larger version (116K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1a. Transverse CT scans obtained in a 41-year-old woman with FNH. (a) Section obtained during the hepatic arterial phase shows a round mass that demonstrates intense homogeneous enhancement with a smooth margin and a small central scar (arrow). (b) Section obtained during the portal venous phase at the same level. The mass (solid arrows) is isoattenuating with the normal hepatic parenchyma and can be identified by the scar (open arrow) that has decreased in size due to partial enhancement.

 


View larger version (117K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1b. Transverse CT scans obtained in a 41-year-old woman with FNH. (a) Section obtained during the hepatic arterial phase shows a round mass that demonstrates intense homogeneous enhancement with a smooth margin and a small central scar (arrow). (b) Section obtained during the portal venous phase at the same level. The mass (solid arrows) is isoattenuating with the normal hepatic parenchyma and can be identified by the scar (open arrow) that has decreased in size due to partial enhancement.

 
Histopathologic confirmation of FNH was based on demonstration of a mass with a central stellate scar that contained normal-appearing hepatocytes, Kupffer cells, and blood vessels, which were arranged into nodules and surrounded by fibrous septa containing a variable amount of primitive bile ductules. There were 27 women and two men (age range, 22–70 years; mean age, 39 years) with FNH. Tumor size ranged from 15 to 100 mm (mean size, 46 mm; median size, 40 mm).

Seventy-eight patients with pathologically proven fibrolamellar HCC were identified. Forty-two of these patients had undergone abdominal CT, but CT scans of 12 patients could not be located and were probably purged (images from 1994 and earlier have been purged at our institution). A central scar was demonstrated in 20 of the remaining 30 CT scans, and these were included in the study (Fig 2). Eleven of the 20 patients with fibrolamellar HCC underwent resection, and the remaining nine patients had core-biopsy proof of diagnosis. Histopathologic confirmation of fibrolamellar HCC was based on demonstration of large, polygonal, eosinophilic malignant hepatocytes that were surrounded by an abundant, collagenous fibrous stroma arranged in a lamellar distribution without underlying cirrhosis. There were 11 male and nine female patients (age range, 15–56 years; mean age, 29 years) with fibrolamellar HCC. Tumor size ranged from 50 to 190 mm (mean size, 140 mm; median size, 140 mm).



View larger version (120K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 2a. Images obtained in an 18-year-old woman with fibrolamellar HCC. (a) Unenhanced transverse CT scan demonstrates a large, heterogeneous hypoattenuating mass that replaces most of the left hepatic lobe. The central scar is not well seen, but there are central coarse calcifications (arrow). (b) Hepatic arterial phase image obtained at the same level shows heterogeneous intense enhancement of the same mass (open arrows). There are two satellite lesions (solid white arrows), and the surface lobulation, central scar (solid black arrow), and calcifications within the scar are seen more clearly. (c) Photograph of the resected specimen. Note the central scar (arrow) and lobulated surface.

 


View larger version (123K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 2b. Images obtained in an 18-year-old woman with fibrolamellar HCC. (a) Unenhanced transverse CT scan demonstrates a large, heterogeneous hypoattenuating mass that replaces most of the left hepatic lobe. The central scar is not well seen, but there are central coarse calcifications (arrow). (b) Hepatic arterial phase image obtained at the same level shows heterogeneous intense enhancement of the same mass (open arrows). There are two satellite lesions (solid white arrows), and the surface lobulation, central scar (solid black arrow), and calcifications within the scar are seen more clearly. (c) Photograph of the resected specimen. Note the central scar (arrow) and lobulated surface.

 


View larger version (134K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 2c. Images obtained in an 18-year-old woman with fibrolamellar HCC. (a) Unenhanced transverse CT scan demonstrates a large, heterogeneous hypoattenuating mass that replaces most of the left hepatic lobe. The central scar is not well seen, but there are central coarse calcifications (arrow). (b) Hepatic arterial phase image obtained at the same level shows heterogeneous intense enhancement of the same mass (open arrows). There are two satellite lesions (solid white arrows), and the surface lobulation, central scar (solid black arrow), and calcifications within the scar are seen more clearly. (c) Photograph of the resected specimen. Note the central scar (arrow) and lobulated surface.

 
Seventeen large hemangiomas (>3.5 cm) with a central scar (Fig 3) were identified, but two were excluded from the study because CT scans were not available for review (they were obtained prior to 1994 and purged). The total number of patients with hemangiomas demonstrated on CT scans during this period is unknown. Pathologic proof of diagnosis was obtained for six patients: One patient underwent liver transplantation, and five patients underwent resection. In all six cases, a fibrous central scar was demonstrated at pathologic examination. The other nine patients with hemangioma were followed up for 12–60 months (mean follow-up, 27 months). Confirmatory magnetic resonance (MR) imaging was performed for three of these patients; the remaining six underwent repeat CT. There were seven men and eight women (age range, 33–77 years; mean age, 59 years) with hemangioma. Tumor size ranged from 35 to 270 mm (mean size, 110 mm; median size, 80 mm).



View larger version (151K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 3a. Transverse CT scans obtained in a 67-year-old man with a large hemangioma. (a) Section obtained during the hepatic arterial phase shows a large lobulated mass (solid arrows) that replaces the right hepatic lobe and demonstrates nodular enhancement (open arrows) that is isoattenuating with the aorta. There is an irregular, cleftlike, central hypoattenuating scar. (b) Section obtained during the portal venous phase at the same level shows more nodular enhancement of the mass, which is still isoattenuating with the aorta. The irregular, elongated, hypoattenuating central scar (arrow) is seen more clearly with the increase in lesion enhancement.

 


View larger version (140K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 3b. Transverse CT scans obtained in a 67-year-old man with a large hemangioma. (a) Section obtained during the hepatic arterial phase shows a large lobulated mass (solid arrows) that replaces the right hepatic lobe and demonstrates nodular enhancement (open arrows) that is isoattenuating with the aorta. There is an irregular, cleftlike, central hypoattenuating scar. (b) Section obtained during the portal venous phase at the same level shows more nodular enhancement of the mass, which is still isoattenuating with the aorta. The irregular, elongated, hypoattenuating central scar (arrow) is seen more clearly with the increase in lesion enhancement.

 
Imaging
All CT studies had been performed with HiLight Advantage or Hispeed Advantage scanners (GE Medical Systems, Milwaukee, Wis). All patients received both oral and intravenous contrast material and underwent contrast-enhanced CT of the abdomen. Patients received 125–150 mL of 60% iodinated contrast medium (iothalamate meglumine [Conray 60] or ioversol [Optiray 350]; Mallinckrodt Medical, St Louis, Mo), which was administered intravenously at a rate of 2–4 mL/sec with a power injector (model OP 100; Medrad, Pittsburgh, Pa). Scan delay was 25–30 seconds for hepatic arterial phase imaging and 60–70 seconds for portal venous phase imaging. Delayed imaging of the liver was performed 10–20 minutes after initiation of intravenous contrast material administration. Collimation was 5–7 mm for helical CT and 7 mm for conventional (nonhelical) CT.

Sixty-four lesions were evaluated, including 29 cases of FNH, 20 fibrolamellar HCCs, and 15 hemangiomas. Fifty-two patients with 23 cases of FNH, 15 fibrolamellar HCCs, and 14 large hemangiomas underwent helical CT, and 12 patients with six cases of FNH, five fibrolamellar HCCs, and one hemangioma underwent conventional CT. Only one lesion per patient was analyzed; therefore, the number of tumors and patients was equivalent. Multiphase (ie, unenhanced, arterial phase, and portal venous phase) CT was performed in 22 patients with FNH, in five patients with fibrolamellar HCC, and in four patients with a large hemangioma. These five patients with fibrolamellar HCC and four of seven patients with FNH underwent only unenhanced and portal venous phase imaging. The three remaining patients with FNH and the four patients with large hemangioma underwent only portal venous phase imaging or late hepatic arterial phase imaging (some underwent delayed imaging). Delayed imaging of the liver had been performed in 12 patients with FNH, in seven patients with fibrolamellar HCC, and in 10 patients with large hemangioma.

A single tumor (ie, the only lesion per patient that contained a scar) was chosen for evaluation in each patient, although readers were not blinded to the presence of any additional lesions.

Image Evaluation
Each of the 64 CT scans were evaluated retrospectively and independently by six readers who had knowledge of the diagnosis of "liver tumor with central scar" but were blinded to the specific diagnosis and any clinical information other than patient age and sex. The six readers included two faculty radiologists (J.V.F. and J.M.L., each with 6 years of experience), one abdominal imaging fellow (J.S.W.), two senior residents (D.R.A. and G.C., each with 3 years of training), and one junior resident (O.A., with 2 years of training). The readers were not provided with any special training other than a short printed summary of what had been reported as "typical" findings of the three tumor types, including morphologic and radiologic tumor characteristics and other findings, such as lymphadenopathy and metastases (Table 1) (119).


View this table:
[in this window]
[in a new window]

 
TABLE 1. CT Findings Useful in Differentiating Liver Tumors with Central Scars

 
On individual data entry sheets, readers were asked to record their confidence in diagnosing the specific tumor type (ie, FNH, fibrolamellar HCC, or hemangioma) and to record the various specific CT findings that may allow differentiation of liver tumors with central scars (Table 1). The degree of confidence was graded as 0 (absent), 1 (probably absent), 2 (possibly present), 3 (probably present), and 4 (definitely present).

The readers also evaluated large tumor size (>10 cm), tumor margins (sharp or ill defined), tumor surface (smooth or lobulated), and homogeneity. The tumor was considered homogeneous if it enhanced to the same degree throughout, with the exception of the scar and radiating septa. A capsule or pseudocapsule was considered present when a thin, curvilinear border surrounded the tumor and distinctly differed in attenuation from the adjacent liver parenchyma on unenhanced or enhanced images. The readers evaluated the presence of intralesional calcifications, as well as invasion of the hepatic vessels or bile ducts. The attenuation of the tumor relative to normal hepatic parenchyma was evaluated on unenhanced, hepatic arterial phase, portal venous phase, and delayed images when available. Isoattenuation with blood vessels and nodular centripetal enhancement were evaluated subjectively.

A tumor scar was defined as a central or eccentric area of attenuation that differed from the rest of the tumor on unenhanced or contrast-enhanced images. Scar characteristics that were recorded included scar size larger or smaller than 2 cm, delayed scar enhancement, and presence of radiating septa (defined as linear structures radiating peripherally from the scar).

Other findings, such as presence of extrahepatic metastases and lymphadenopathy (short-axis diameter of lymph nodes, >1.5 cm), were also evaluated.

Statistical Analysis
A biostatistician (W.L.) participated in the study design and review of the data. Interobserver agreement (ie, reliability) was evaluated with the Cronbach {alpha}. We considered an {alpha} value of more than 0.80 to represent excellent agreement (23) and values of 0.71–0.80 and 0.60–0.70 to represent good or acceptable agreement, respectively. Values of less than 0.60 were considered to represent poor agreement. Individual performance was evaluated according to the area under the receiver operating characteristic curve (Az), which was calculated with a nonparametric method (24,25). When making a comparison among readers, or when the results for readers were combined, we used a method that considered the correlation between readers, since all readers reviewed the same set of cases.

The percentage of correct diagnoses of tumor type (ie, sensitivity) was calculated for each reader. The tumor type rated with the highest degree of confidence was used as the diagnosis (eg, if a reader rated his diagnosis of hemangioma as "3," and fibrolamellar HCC received a "1" and FNH a "0," his diagnosis for that lesion was listed as "hemangioma"). The statistical significance of the differences in both sensitivity and degree of confidence for diagnosis between pairs of readers was evaluated by using the McNemar test (26) (Table 2). The McNemar test compares the dichotomous outcome of whether reader 1 correctly diagnoses each case with the dichotomous outcome of whether reader 2 correctly diagnoses each case.


View this table:
[in this window]
[in a new window]

 
TABLE 2. Sensitivity and Overall Accuracy of Readers in the Diagnoses of Tumor Type

 
CT findings that reliably allowed differentiation of the various tumor types were identified by means of nonparametric one-way analysis of variance (ANOVA) (ie, the Kruskal-Wallis test) (26) for each of the six readers. The Kruskal-Wallis test was performed separately for each reader and for each CT finding. This test, which is similar to ANOVA, determines whether the score for a CT finding is significantly different among the three tumor types and provides a P value. Therefore, there were six P values for each CT finding. Only those CT findings in which a majority of the six P values were significant were considered useful in differentiating tumor types.

The importance of other factors (ie, patient age and sex) in differentiating various tumor types was also assessed by using one-way ANOVA for patient age and the {chi}2 test (applied to the appropriate contingency table) for patient sex. We did not evaluate clinical factors such as liver function tests, tumor markers, clinical symptoms, or signs that may also be important in differentiating these tumors.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Interobserver agreement (ie, reliability) for diagnosing the tumor type and recognizing distinguishing features among tumors with central scars is presented in Table 3. There was excellent agreement between readers in diagnosing all three tumor types and good or excellent interobserver agreement in most of the CT findings thought to be typical of a specific tumor type. There was poor agreement between readers only in evaluating the number of lesions per patient.


View this table:
[in this window]
[in a new window]

 
TABLE 3. Interobserver Agreement of Diagnosis and CT Findings

 
The sensitivity for diagnosis of tumor type was highest for fibrolamellar HCC and lowest for FNH (Table 2). Although the faculty readers (readers 1 and 2) achieved a higher sensitivity of diagnosis than that of the fellow and residents, the difference in sensitivity achieved by the subgroups of readers (ie, faculty, fellow, and senior and junior residents) was not statistically significant according to results of the McNemar test. There was no statistically significant difference in the degree of confidence for diagnosis between the various subgroups of readers according to results of the McNemar test.

The individual performance of readers in the diagnosis of various tumors was evaluated according to Az values, which were calculated by using nonparametric analysis (Table 4) and were found to be accurate for all readers (average Az, 0.81–0.90). The faculty readers were slightly more accurate than the other readers, with an average Az of 0.87 and 0.90. The Az of the residents and fellow were 0.81–0.88 and 0.87, respectively. The difference in accuracy of diagnosis between subgroups of readers was not statistically significant. Fibrolamellar HCC was diagnosed most accurately by all readers, followed by large hemangioma and FNH. We also generated an average Az value to evaluate the performance of the group as a whole, and found it to be very accurate, with an average Az of 0.91. Fibrolamellar HCC was diagnosed most accurately by the group (Az = 0.91), followed by hemangioma (Az = 0.86) and FNH (Az = 0.83).


View this table:
[in this window]
[in a new window]

 
TABLE 4. Reader Performance

 
The final step of our analysis was to evaluate CT and clinical findings that may distinguish FNH, fibrolamellar HCC, and large hemangioma by using the nonparametric one-way ANOVA (ie, Kruskal-Wallis) test (Table 5). Eleven of the 21 CT findings that were evaluated were found to be statistically significant distinguishing features. Patient age and sex were also found to be distinguishing features by using the {chi}2 test and one-way ANOVA with P values of less than .001.


View this table:
[in this window]
[in a new window]

 
TABLE 5. CT Findings that Significantly Distinguished Tumor Types

 

    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Liver tumors with central scars are commonly encountered and may be benign or malignant. From our experience in evaluating multiple patients who have hepatic tumors with central scars, we believe that CT allows accurate differentiation of these tumors. Multiple reports have been published on FNH, fibrolamellar HCC, and large hemangioma, but to the best of our knowledge, this is the only study that has evaluated the performance of radiologists in distinguishing these tumors by using specific CT criteria in a setting free of most sources of bias.

We were encouraged to find that there was excellent interobserver agreement in diagnosing the tumors and in recognizing almost all of the CT findings that were evaluated. All of the radiologists performed well, and there was no significant difference in performance between individuals or groups (ie, resident, fellow, and faculty groups).

Findings that were found to be statistically significant in differentiating the three tumor types were related to epidemiologic and imaging factors, including patient age and sex, tumor and scar characteristics, tumor enhancement patterns, and other findings.

More than 80%–95% of patients with FNH are women (3,5). A female predominance for hemangioma has been cited as well, although this was not evident in our population of patients who had large hemangiomas with central scarring (14). Fibrolamellar HCC shows no particular sex predominance, but it is characteristically discovered in adolescents and young adults, as shown in our study (911). FNH can be discovered at any age, although it has been reported most commonly in young women. The mean age of FNH patients in our study was 39 years, which closely matches that reported by other investigators (15). Large hemangiomas are usually detected in older patients, with a mean age of 54 years in our study and 45 years in another report (16).

Tumor Morphology
We found a few important distinguishing tumoral imaging features, including large tumor size (>10 cm), tumor surface lobulation, and intratumoral calcifications. FNH usually appears as a lesion smaller than 5 cm, whereas fibrolamellar HCCs and hemangiomas with central scars tend to be larger (1,2,4,5). Fibrolamellar HCC varies in size from 5 to 20 cm, with an average reported size of 13–14 cm (912) (average size was 14 cm in our study). Large or giant hepatic hemangiomas are defined as larger than 4 cm (17), 6 cm (18), or even 10 cm by various authors (19), with an average size of 11 cm (as in our study). The tumor surface can be an important distinguishing feature among the three tumor types. Fibrolamellar HCC usually has a lobulated margin (9,10,12) (in up to 65% of cases, according to Ichikawa et al [9]), whereas FNH commonly has a well-marginated, smooth surface (1,2,4), especially in tumors smaller than 3 cm (1).

Hepatic hemangiomas tend to have a rounded lobular margin (15). Calcification is typical of fibrolamellar HCC, with a reported incidence of 35%–68% (912). Calcifications may be punctate, nodular, or stellate and are usually small (<5 mm), few (one to three in number), and almost always located near the center of the tumor (9,10). Calcification is rarely seen in FNH. In a prior report (1) in which 124 FNH tumors were evaluated with CT, only one lesion had a calcification (0.8%). In another study (7) in which 357 cases of FNH were evaluated with CT, MR imaging, and ultrasonography, five lesions (1.4%) had a calcification. Calcifications have rarely been reported with sclerosed or hyalinized and giant hemangiomas (14,27,28). The calcifications may be marginal or central; large and coarse; or multiple, small, and punctate (eg, phleboliths). Although intralesional calcifications may be seen with any of the three types of tumors, their rarity in FNH and hemangioma and high frequency in fibrolamellar HCC make this an important differentiating feature, especially when evaluated with regard to other distinguishing imaging features.

Other tumor characteristics, including margins, presence of radiating fibrous septa or pseudocapsules, and number of lesions, did not prove as useful in distinguishing the three types of tumors.

Scar Characteristics
Fibrolamellar HCC demonstrates a central scar in up to 20%–71% of cases (912). It is typically large and may be broad or stellate, eccentric or central. Although some authors reported that the scar does not enhance on delayed images and that absence of scar enhancement can be used to distinguish fibrolamellar HCC from FNH (13), results of larger and more recent studies indicate that the scar retains contrast material and becomes hyperattenuating compared with the rest of the tumor in 25%–56% of cases (9,10). A central scar is histologically present in almost all patients with FNH. However, it may be subtle and extremely small and is identified with the use of CT in 30%–50% of cases (1,3,4,6). Presence of a central scar is clearly related to lesion size. Thirty-five percent of small areas of FNH (<3 cm) and 65% of large areas of FNH (>3 cm) demonstrated the scar in a recent article (1). The scar is typically thin and small and is hypoattenuating compared with the rest of the FNH on unenhanced, hepatic arterial phase, and portal venous phase images. On delayed images, the scar often becomes hyperattenuating because of contrast material retention (1,2,5,6). Large hemangiomas usually demonstrate cleftlike central or eccentric areas of scarring that constitute areas of fibrosis, sclerosis (ie, hyalinization), cystic degeneration, or thrombosis. These areas have a variable shape and size and usually do not demonstrate delayed contrast enhancement (16).

The only scar characteristic that we found to be a statistically significant differentiating feature was a scar size of larger than 2 cm, which indicated fibrolamellar HCC and sometimes hemangioma. Delayed scar enhancement and presence of fibrous radiating septa from the scar were not statistically significant features.

Tumor Enhancement Patterns
Tumor heterogeneity was found to be an important differentiating feature. Tumor heterogeneity is typical of fibrolamellar HCC and stems from its mixed content of eosinophilic neoplastic cells interspersed in collagen and fibrotic tissues and from intratumoral necrosis and hemorrhage (9,10,12,13). Fibrolamellar HCC is almost always heterogeneous (in 90% of cases, according to Ichikawa et al [9]) on unenhanced images and demonstrates heterogeneous enhancement on hepatic arterial phase images (9,10,12,13) (in 80% of cases, according to Ichikawa et al [9]). FNH, on the contrary, is usually homogeneous (15) and isoattenuating (40%–48%) to slightly hypoattenuating (42%–57%) (1,4) compared with normal liver tissue on unenhanced images. FNH demonstrates a homogeneous, immediate, bright enhancement in nearly all cases (89%–100%), with the exception of the central scar (1,2,4). Large hemangiomas are also relatively heterogeneous on unenhanced and contrast-enhanced images, but they demonstrate a characteristic enhancement pattern. This pattern of centripetal nodular enhancement with progressive filling (29,30), as well as isoattenuation with the blood vessels on unenhanced and contrast-enhanced images (30), is particular to hemangioma.

The last enhancement feature that we found to be a significant differentiating feature was isoattenuation with normal liver tissue on portal venous phase images. The enhancement of fibrolamellar HCC becomes less heterogeneous and pronounced on portal venous phase (as opposed to arterial phase) images, and the tumor is most commonly isoattenuating or hypoattenuating compared with normal liver tissue. Because of its prominent fibrous component, it may occasionally be hyperattenuating compared with normal liver tissue (9,10). FNH demonstrates homogeneous but decreased enhancement on portal venous phase (as opposed to arterial phase) images and is isoattenuating with normal liver tissue in most cases (72%–89%) (1,4,5), although it may be hypoattenuating or hyperattenuating (1,3,5). Hepatic hemangiomas are easily diagnosed on portal venous phase images according to their characteristic enhancement pattern. They usually demonstrate progressive filling and become hyperattenuating compared with liver tissue (paralleling hepatic vessels) in most cases, with the exception of the central area of scarring.

Other Findings
Patients with fibrolamellar HCC frequently have advanced disease at the time of initial presentation. Lymphadenopathy has been reported in 50%–70% of cases (9,10) and is not a feature of hemangiomas or FNH—therefore, it is an important distinguishing feature. Lymphadenopathy almost always involves the hepatic hilum and hepatoduodenal ligament and may be extensive in 60% of cases, involving multiple abdominal and retroperitoneal sites (9,10). Extrahepatic metastases to the lungs, peritoneum, or adjacent organs occur less commonly (20%) (10). Invasion of the hepatic vessels or bile ducts was also found to be an important differentiating feature, but it may be seen in less than 5% of cases of fibrolamellar HCC (9). Venous thrombosis may result from compression of the portal or hepatic veins by an adjacent tumor, which simulates vascular invasion. Portal vein thrombosis may be seen with fibrolamellar HCC (7) but has also been reported rarely with large hemangiomas (14).

Our study is limited to a degree by its retrospective nature, which we believed was unavoidable due to the relative rarity of the tumors. We believe that we were able to minimize most biases by including relatively large numbers of tumors and by avoiding exclusion of cases, other than the few that were not available for review due to purging. We believe that the inclusion of residents and a fellow as readers makes our findings and conclusions more applicable to individuals of various experiential levels.

In conclusion, we found that CT allows accurate differentiation of FNH, fibrolamellar HCC, and large hepatic hemangioma by radiologists with varying levels of experience and expertise.


    ACKNOWLEDGMENTS
 
We thank Howard Rockette, PhD, for his help with the statistical analysis and design of the study and for his constructive review of the manuscript. We also thank our research assistant, Karen M. Pealer, BS, who was invaluable in acquiring and processing data.


    FOOTNOTES
 
Abbreviations: ANOVA = analysis of variance, FNH = focal nodular hyperplasia, HCC = hepatocellular carcinoma

Author contributions: Guarantor of integrity of entire study, M.P.F.; study concepts, A.B., M.P.F.; study design, M.P.F.; literature research, A.B.; clinical studies, all authors; data acquisition, A.B.; data analysis/interpretation, A.B., W.L.; statistical analysis, W.L.; manuscript preparation, A.B., M.P.F.; manuscript definition of intellectual content and editing, M.P.F.; manuscript revision/review and final version approval, all authors.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Brancatelli G, Federle MP, Grazioli L, Blachar A, Peterson MS, Thaete FL. Focal nodular hyperplasia: CT findings with emphasis on multiphasic helical CT in 78 patients. Radiology 2001; 219:61-68.
  2. Mortele KJ, Praet M, Vlierberghe HV, Kunnen M, Ros PR. CT and MR imaging findings in focal nodular hyperplasia of the liver: radiologic-pathologic correlation. AJR Am J Roentgenol 2000; 175:687-692.
  3. Choi CS, Freeny PC. Triphasic helical CT of hepatic focal nodular hyperplasia: incidence of atypical findings. AJR Am J Roentgenol 1998; 170:391-395.
  4. Carlson SK, Johnson CD, Bender CE, Welch TJ. CT of focal nodular hyperplasia of the liver. AJR Am J Roentgenol 2000; 174:705-712.
  5. Buetow PC, Pantongrag-Brown L, Buck JL, Ros PR, Goodman ZD. Focal nodular hyperplasia of the liver: radiologic-pathologic correlation. RadioGraphics 1996; 16:369-388.
  6. Shamsi K, DeShepper A, Degryse H, et al. Focal nodular hyperplasia of the liver: radiologic findings. Abdom Imaging 1993; 18:32-38.
  7. Caseiro-Alves F, Zins M, Mahfouz AE, et al. Calcification in focal nodular hyperplasia: a new problem for differentiation from fibrolamellar hepatocellular carcinoma. Radiology 1996; 198:889-892.
  8. Mahfouz AE, Hamm B, Taupitz M, Wolf KJ. Hypervascular liver lesions: differentiation of focal nodular hyperplasia from malignant tumors with dynamic gadolinium-enhanced MR imaging. Radiology 1993; 186:133-138.
  9. Ichikawa T, Federle MP, Grazioli L, Madariaga J, Nalesnik M, Marsh W. Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. Radiology 1999; 213:352-361.
  10. McLarney JK, Rucker PT, Bender GN, Goodman ZD, Kshitani N, Ros PR. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. RadioGraphics 1999; 19:453-471.
  11. Friedman AC, Lichtenstein JE, Goodman ZD, Fishman EK, Siegelman SS, Dachman AH. Fibrolamellar hepatocellular carcinoma. Radiology 1985; 157:583-587.
  12. Brandt DJ, Johnson CD, Stephens DH, Weilan LH. Imaging of fibrolamellar hepatocellular carcinoma. AJR Am J Roentgenol 1988; 151:295-299.
  13. Corrigan K, Semelka RC. Dynamic contrast-enhanced MR imaging of fibrolamellar hepatocellular carcinoma. Abdom Imaging 1995; 20:122-125.
  14. Vilgrain V, Boulos L, Vullierme MP, Denys A, Terris B, Menu Y. Imaging of atypical hemangiomas of the liver with pathologic correlation. RadioGraphics 2000; 20:379-397.
  15. Semelka RC, Brown ED, Ascher SM, et al. Hepatic hemangioma: a multi-institutional study of appearance on T2-weighted and serial gadolinium-enhanced gradient-echo MR images. Radiology 1994; 192:401-406.
  16. Choi BI, Han MC, Park JH, Kim SH, Han MH, Kim CW. Giant cavernous hemangioma of the liver: CT and MR imaging in 10 cases. AJR Am J Roentgenol 1989; 152:1221-1226.
  17. Nelson RD, Chezmar JL. Diagnostic approach to hepatic hemangiomas. Radiology 1990; 176:11-13.
  18. Scatariage JC, Kenny JM, Fishman EK, Herlong FH, Siegelman SS. CT of giant cavernous hemangioma. AJR Am J Roentgenol 1987; 149:83-85.
  19. Edmonson HA, Peters RL. Neoplasms of the liver. In: Schift L, Scift ET, eds. Diseases of the liver. Philadelphia, Pa: Lippincott, 1982; 1114-1145.
  20. Yoshikawa J, Matsui O, Kadoya M, Gabata T, Arai K, Takashima T. Delayed enhancement of fibrotic areas in hepatic masses: CT-pathologic correlation. J Comput Assist Tomogr 1992; 16:206-211.
  21. Rummeny E, Weissleder R, Sironi S, et al. Central scars in liver tumors: MR features, specificity, and pathologic correlation. Radiology 1989; 171:323-326.
  22. Peterson MS, Murakami T, Baron RL. MR imaging patterns of gadolinium retention within liver neoplasms. Abdom Imaging 1998; 23:592-599.
  23. Cronbach LJ. Essentials of psychological testing 4th ed. New York, NY: Harper & Row, 1984; 170.
  24. DeLong ER, DeLong DM. Comparing the areas under two or more correlated reciever operating curves: a nonparametric approach. Biometrics 1988; 44:837-845.
  25. Hanley JA, McNeil BJ. Comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148:839-843.
  26. McNemar Q. Note on the sampling error of differences between correlated proportions or percentages. Psychometrika 1947; 12:153-157.
  27. Mathieu D, Rahmouni A, Vasile N, et al. Sclerosed liver hemangioma mimicking malignant tumor at MR imaging: pathologic correlation. J Magn Reson Imaging 1994; 4:506-508.
  28. Mitsudo K, Watanabe Y, Saga T, et al. Nonenhanced hepatic cavernous hemangioma with multiple calcifications: CT and pathologic correlation. Abdom Imaging 1995; 20:459-461.
  29. Ashida , Fishman EK, Zerhouni EA, Herlong FH, Siegelman SS. Computed tomography of hepatic cavernous hemangioma. J Comput Assist Tomogr 1987; 11:455-460.
  30. Quinn SF, Benjamin GG. Hepatic cavernous hemangiomas: simple diagnostic sign with dynamic bolus CT. Radiology 1992; 182:545-548.



This article has been cited by other articles:


Home page
Am. J. Roentgenol.Home page
M. E. Lockhart, F. N. Tessler, C. L. Canon, J. K. Smith, M. C. Larrison, N. S. Fineberg, B. P. Roy, and R. H. Clements
Internal Hernia After Gastric Bypass: Sensitivity and Specificity of Seven CT Signs with Surgical Correlation and Controls
Am. J. Roentgenol., March 1, 2007; 188(3): 745 - 750.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
Z.-C. Zeng, Z.-Y. Tang, J. Fan, J. Zhou, L.-X. Qin, S.-L. Ye, H.-C. Sun, B.-L. Wang, J.-Y. Zhang, Y. Yu, et al.
Radiation Therapy for Adrenal Gland Metastases from Hepatocellular Carcinoma
Jpn. J. Clin. Oncol., February 1, 2005; 35(2): 61 - 67.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2232010801v1
223/2/532    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blachar, A.
Right arrow Articles by Li, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blachar, A.
Right arrow Articles by Li, W.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE